Overview
At a Glance
All five FDA-approved botulinum toxin type A products — Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA), and Daxxify (daxibotulinumtoxinA) — share the same core mechanism: blocking nerve signals to muscles. They differ in formulation, onset speed, spread pattern, duration of effect, and price. Units are not interchangeable between brands. Most treatments last 3–4 months; Daxxify may last 6–9 months. Typical cost ranges from $10–$20 per unit.Botulinum toxin type A is the most widely performed cosmetic procedure in the world. These injectable neuromodulators temporarily reduce muscle activity by blocking the release of acetylcholine — the chemical messenger that signals muscles to contract. When injected into specific facial muscles, the result is a visible softening of dynamic wrinkles (lines that form from repeated facial expressions such as frowning, squinting, or raising the eyebrows).
Although "Botox" has become a generic term in popular culture, there are now five distinct FDA-approved botulinum toxin type A products on the market. Each is manufactured by a different company using different production processes, resulting in products that — while mechanistically similar — have clinically meaningful differences in formulation, unit potency, diffusion characteristics, onset, and duration (Nestor et al., 2017).
These products are prescription medications that must be administered by a licensed healthcare provider. The choice between them depends on several factors: the specific treatment area, desired onset speed, how long the patient wants results to last, individual response history, provider experience, and cost considerations.
The Five FDA-Approved Botulinum Toxin Type A Products
| Brand Name | Generic Name | Manufacturer | FDA Cosmetic Approval |
|---|---|---|---|
| Botox Cosmetic | OnabotulinumtoxinA | Allergan (AbbVie) | 2002 |
| Dysport | AbobotulinumtoxinA | Galderma | 2009 |
| Xeomin | IncobotulinumtoxinA | Merz Aesthetics | 2011 |
| Jeuveau | PrabotulinumtoxinA | Evolus | 2019 |
| Daxxify | DaxibotulinumtoxinA | Revance Therapeutics | 2022 |
Key Differences at a Glance
While all five products block acetylcholine release at the neuromuscular junction, they differ in several important ways:
- Complexing proteins: Botox, Dysport, and Jeuveau contain complexing proteins (hemagglutinins) that surround the active neurotoxin. Xeomin is a "naked" toxin with complexing proteins removed. Daxxify uses a novel peptide stabilizer instead of human serum albumin or complexing proteins.
- Unit equivalence: Units are not interchangeable between products. One unit of Botox is not equivalent to one unit of Dysport. Conversion ratios are used in clinical practice (detailed in the Brand Comparison tab).
- Onset: Dysport tends to show results slightly faster (24–48 hours) than Botox or Xeomin (3–5 days). Daxxify onset is similar to Botox.
- Duration: Most products last approximately 3–4 months. Daxxify has demonstrated a median duration of approximately 6 months, with some patients reporting effects lasting up to 9 months (Bertucci & Solish, 2022).
- Spread (diffusion): Dysport tends to diffuse more broadly from the injection site, which can be advantageous for large surface areas (like the forehead) but requires careful technique near delicate areas. Botox and Xeomin have more localized diffusion patterns.
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
How It Works
The Neuromuscular Junction
Under normal conditions, when a motor nerve fires, the nerve terminal releases acetylcholine (ACh) into the neuromuscular junction — the gap between nerve and muscle. ACh binds to receptors on the muscle fiber, triggering contraction. This process depends on a set of proteins called the SNARE complex (soluble N-ethylmaleimide-sensitive factor attachment protein receptor), which enables the vesicles containing ACh to fuse with the nerve terminal membrane and release their contents (Brunger & Bhagat, 2001).
How Botulinum Toxin Disrupts This Process
Botulinum toxin type A specifically cleaves SNAP-25 (synaptosomal-associated protein of 25 kDa), one of the three SNARE complex proteins. When SNAP-25 is cleaved, the vesicle fusion machinery cannot function — ACh vesicles cannot release their contents into the junction, and the muscle does not receive the signal to contract (Aoki, 2004).
The process occurs in several steps:
- Binding: The heavy chain of the toxin binds to specific receptors on the presynaptic nerve terminal (SV2 receptors and gangliosides).
- Internalization: The toxin is taken into the nerve terminal via receptor-mediated endocytosis.
- Translocation: The light chain of the toxin is released from the endosome into the cytoplasm of the nerve terminal.
- Cleavage: The light chain (a zinc-dependent endopeptidase) cleaves SNAP-25, disabling the SNARE complex.
- Blockade: ACh release is inhibited, and the muscle relaxes.
Why the Effect Is Temporary
The clinical effect of botulinum toxin is temporary because the nerve terminal gradually recovers. New SNAP-25 is synthesized, and the nerve terminal re-establishes functional connections with the muscle through a process called axonal sprouting. Over approximately 3–4 months (longer for Daxxify), the neuromuscular junction regains full function and muscle contraction returns (Nestor et al., 2017).
How the Five Products Differ Mechanistically
All five products contain the same 150-kDa botulinum toxin type A core neurotoxin and cleave the same SNAP-25 target. Their differences lie in formulation, not mechanism:
| Feature | Botox | Dysport | Xeomin | Jeuveau | Daxxify |
|---|---|---|---|---|---|
| Complexing proteins | Yes (900 kDa complex) | Yes (500–900 kDa complex) | No (150 kDa pure toxin) | Yes (900 kDa complex) | No (150 kDa pure toxin) |
| Stabilizer | Human serum albumin (HSA) | HSA + lactose | HSA + sucrose | HSA | RTP004 peptide (no HSA) |
| Molecular weight | ~900 kDa | ~500–900 kDa | ~150 kDa | ~900 kDa | ~150 kDa |
| Theoretical significance | Complexing proteins may slow diffusion and extend local activity | Smaller complex size may contribute to broader spread | No complexing proteins = lower risk of antibody formation to non-toxin proteins | Similar to Botox formulation | Peptide stabilizer may contribute to longer duration |
Why Daxxify Lasts Longer
Daxxify uses a proprietary peptide excipient (RTP004) instead of human serum albumin as a stabilizer. This peptide has a positive charge that may enhance the binding affinity of the toxin to nerve terminal membranes, resulting in more efficient uptake and longer-lasting SNAP-25 inhibition. In pivotal trials, Daxxify demonstrated a median duration of approximately 6 months — roughly 50% longer than traditional BoNT-A products (Bertucci & Solish, 2022).
Antibody Formation
With repeated use of any botulinum toxin product, the immune system may develop neutralizing antibodies against the toxin, reducing its effectiveness over time. This is uncommon but more likely with higher doses and shorter intervals between treatments. Xeomin's lack of complexing proteins was designed in part to reduce the antigenic load and potentially lower the risk of antibody-mediated treatment failure (Frevert, 2015). In clinical practice, true immunoresistance to BoNT-A remains rare in cosmetic applications where doses are relatively low.
Go Deeper
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Brand Comparison
Head-to-Head Comparison
| Feature | Botox | Dysport | Xeomin | Jeuveau | Daxxify |
|---|---|---|---|---|---|
| Generic name | OnabotulinumtoxinA | AbobotulinumtoxinA | IncobotulinumtoxinA | PrabotulinumtoxinA | DaxibotulinumtoxinA |
| Manufacturer | Allergan (AbbVie) | Galderma | Merz Aesthetics | Evolus | Revance Therapeutics |
| FDA cosmetic approval | 2002 | 2009 | 2011 | 2019 | 2022 |
| Complexing proteins | Yes | Yes | No | Yes | No |
| Stabilizer | Human serum albumin | HSA + lactose | HSA + sucrose | HSA | Peptide (RTP004) |
| Onset | 3–5 days | 24–48 hours | 3–4 days | 2–3 days | 3–5 days |
| Peak effect | 10–14 days | 7–14 days | 10–14 days | 10–14 days | 14 days |
| Duration | 3–4 months | 3–4 months | 3–4 months | 3–4 months | 6–9 months |
| Diffusion / spread | Moderate | Higher (broader spread) | Moderate | Moderate | Moderate |
| Refrigeration | Required (before reconstitution) | Required | Room temperature (before reconstitution) | Required | Required |
| Cost per unit | $10–$17 | $4–$6 (per Dysport unit) | $10–$15 | $8–$14 | $12–$20 |
| Cost per treatment area (glabellar) | $200–$340 | $200–$300 | $200–$300 | $160–$280 | $480–$800 |
Unit Conversion
Units are not interchangeable between brands. Each product has its own unit measurement based on its specific bioassay. Using the wrong conversion can lead to underdosing (inadequate result) or overdosing (excessive weakness, adverse effects). The following conversion ratios are commonly used in clinical practice:
| From | To | Approximate Ratio | Example |
|---|---|---|---|
| Botox | Dysport | 1 : 2.5–3 | 20 U Botox ≈ 50–60 U Dysport |
| Botox | Xeomin | 1 : 1 | 20 U Botox ≈ 20 U Xeomin |
| Botox | Jeuveau | 1 : 1 | 20 U Botox ≈ 20 U Jeuveau |
| Botox | Daxxify | 1 : 2 (approximately) | 20 U Botox ≈ 40 U Daxxify |
| Dysport | Botox | 2.5–3 : 1 | 60 U Dysport ≈ 20–24 U Botox |
Note: These are approximate clinical ratios based on published studies and expert consensus (Scaglione, 2016). Individual response varies, and providers may adjust based on patient history and treatment goals. The FDA has not established official conversion ratios.
Choosing Between Products
The following considerations may guide the choice between products, in consultation with a qualified provider:
- Fastest onset needed: Dysport tends to show visible results sooner (24–48 hours), making it a common choice when patients have a specific event or timeline.
- Longest duration desired: Daxxify is the only product with a demonstrated median duration of approximately 6 months, with some patients seeing effects for up to 9 months. This means fewer office visits per year but higher per-treatment cost.
- Large treatment areas (forehead): Dysport's broader diffusion pattern can be advantageous for treating the forehead, potentially producing a smoother result with fewer injection points.
- Precision in small areas (crow's feet, lip flip): Botox and Xeomin, with more contained diffusion, may offer more precise targeting near areas where unwanted spread could cause complications (e.g., near the eyelid).
- Concern about antibody formation: Xeomin's lack of complexing proteins may theoretically reduce the risk of immunoresistance in patients requiring frequent or high-dose treatments.
- Budget-conscious: Jeuveau is often priced lower than Botox with similar clinical performance, making it an option for cost-sensitive patients. Dysport can also be cost-effective because per-unit pricing is lower (though more units are needed).
- No human-derived ingredients preferred: Daxxify is the only product that does not contain human serum albumin.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Uses
FDA-Approved Cosmetic Indications
| Indication | Botox | Dysport | Xeomin | Jeuveau | Daxxify |
|---|---|---|---|---|---|
| Glabellar lines (frown lines / "11s") | ✓ | ✓ | ✓ | ✓ | ✓ |
| Forehead lines | ✓ | ✓ | — | — | — |
| Lateral canthal lines (crow's feet) | ✓ | — | — | — | — |
Note: Products without FDA approval for a specific area may still be used off-label at the provider's discretion. Off-label use of BoNT-A for cosmetic areas not listed above is extremely common and well-supported by clinical literature.
Common Off-Label Cosmetic Uses
- Forehead lines — widely treated off-label with Xeomin, Jeuveau, and Daxxify (FDA-approved for Botox and Dysport)
- Crow's feet — commonly treated with all five products (FDA-approved for Botox only)
- Bunny lines — lines on the sides of the nose from scrunching
- Lip flip — small doses along the upper lip border to create a subtle lip eversion
- Gummy smile — relaxation of the levator labii superioris to reduce gum visibility when smiling
- Masseter reduction / jawline slimming — injection into the masseter muscle for facial contouring and treatment of bruxism (teeth grinding)
- Platysmal bands (Nefertiti lift) — treatment of vertical neck bands
- Dimpled chin (mentalis) — smoothing of the "orange peel" chin appearance
FDA-Approved Medical Indications
| Medical Indication | Approved Product(s) |
|---|---|
| Chronic migraine (≥15 headache days/month) | Botox |
| Cervical dystonia (involuntary neck muscle contraction) | Botox, Dysport, Xeomin |
| Blepharospasm (involuntary eyelid closure) | Botox, Xeomin |
| Upper limb spasticity | Botox, Dysport, Xeomin |
| Lower limb spasticity | Botox, Dysport |
| Overactive bladder | Botox |
| Axillary hyperhidrosis (excessive underarm sweating) | Botox |
| Strabismus (crossed eyes) | Botox |
| Pediatric upper limb spasticity | Dysport |
Botox holds the broadest range of FDA-approved medical indications among the five products, which reflects its longer market history and the manufacturer's investment in clinical trials across multiple conditions. The other products may be used off-label for similar indications at the provider's discretion.
Emerging and Investigational Uses
- Depression: Preliminary research suggests that glabellar BoNT-A injections may improve depressive symptoms, potentially through the facial feedback hypothesis (reducing frowning reduces negative emotional signaling to the brain). Several randomized controlled trials have reported positive results (Wollmer et al., 2012).
- Scar prevention: Early injection of BoNT-A along wound margins may reduce scar widening by decreasing muscle tension on healing skin.
- Raynaud's phenomenon: BoNT-A injections into the hand have shown benefit in reducing vasospastic episodes in small studies.
- Neuropathic pain: Subcutaneous BoNT-A has been investigated for various chronic pain conditions beyond migraine.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Dosing
Botulinum toxin is a prescription medication. Dosing must be determined by a licensed healthcare provider based on individual anatomy, muscle mass, treatment goals, and medical history. The information below reflects published dosing ranges from clinical trials and expert consensus — it is provided for educational purposes only.
Typical Cosmetic Dosing by Area (Women)
| Treatment Area | Botox (units) | Dysport (units) | Xeomin (units) | Jeuveau (units) | Daxxify (units) |
|---|---|---|---|---|---|
| Glabellar lines ("11s") | 20 | 50 | 20 | 20 | 40 |
| Forehead lines | 10–20 | 25–50 | 10–20 | 10–20 | 20–40 |
| Crow's feet (per side) | 8–12 | 20–30 | 8–12 | 8–12 | 16–24 |
| Bunny lines | 4–8 | 10–20 | 4–8 | 4–8 | 8–16 |
| Lip flip | 2–4 | 5–10 | 2–4 | 2–4 | 4–8 |
| Masseter (per side) | 25–50 | 60–120 | 25–50 | 25–50 | 50–100 |
| Platysmal bands | 20–40 | 50–100 | 20–40 | 20–40 | 40–80 |
Sources: FDA-approved product labeling; Nestor et al., 2017; Scaglione, 2016
Men Require Higher Doses
Male patients typically require 1.5 to 2 times the dose used for women in the same treatment area. This is due to:
- Greater muscle mass: Male facial muscles — particularly the frontalis (forehead), corrugator (glabellar), and masseter (jaw) — are typically larger and stronger than their female counterparts.
- Thicker skin: Male facial skin is generally thicker, which may affect diffusion patterns.
- Stronger contractions: Greater muscle strength requires more toxin to achieve adequate relaxation.
| Treatment Area | Female Dose (Botox units) | Male Dose (Botox units) |
|---|---|---|
| Glabellar lines | 20 | 30–40 |
| Forehead lines | 10–20 | 20–30 |
| Crow's feet (per side) | 8–12 | 12–20 |
| Masseter (per side) | 25–50 | 40–70 |
Reference: Nestor et al., 2017; expert consensus dosing guidelines.
Treatment Intervals
- Botox, Dysport, Xeomin, Jeuveau: Treatments are typically repeated every 3–4 months. Most providers recommend waiting at least 12 weeks between treatments to reduce the risk of antibody development.
- Daxxify: With its longer duration, re-treatment is typically needed every 6–9 months. Some patients may still prefer retreatment at 4–5 months if they notice return of movement earlier.
Maximum Recommended Doses
Each product has recommended maximum doses per treatment session, based on safety data from clinical trials:
| Product | Max Recommended Per Session | Context |
|---|---|---|
| Botox | 360–400 units (medical); 64 units (cosmetic — 3 areas combined) | Higher limits apply to medical indications (e.g., spasticity) |
| Dysport | 1,000 units (medical); 150 units (cosmetic glabellar) | Unit numbers are higher because of Dysport unit definition |
| Xeomin | 400 units (medical); 20 units (cosmetic glabellar) | Similar to Botox limits |
| Jeuveau | 20 units (cosmetic glabellar — only approved indication) | Limited data on higher total doses |
| Daxxify | 40 units (cosmetic glabellar — only approved indication) | Dosing data for other areas still emerging |
Source: Nestor et al. (2017) — Dosing comparisons across BoNT-A products.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Results: What to Expect
Timeline of Results
| Timepoint | What to Expect |
|---|---|
| Day 1 | Small injection marks may be visible. Mild redness or swelling at injection sites is common and resolves within hours. No visible wrinkle improvement yet. |
| Days 2–3 | Dysport and Jeuveau users may begin to notice reduced movement in treated areas. Botox, Xeomin, and Daxxify users typically do not see visible changes yet. |
| Days 3–5 | Reduced muscle movement becomes noticeable for most products. Lines begin to soften when the face is at rest. Full effect is not yet achieved. |
| Days 7–10 | Significant improvement visible. Dynamic lines are markedly reduced. The treated area shows substantially less movement when attempting to frown, raise eyebrows, or squint. |
| Days 10–14 | Peak effect is reached. Maximum wrinkle reduction. This is the ideal time for a follow-up assessment with your provider to determine if a touch-up is needed. |
| Months 2–3 | Effect remains stable for most patients. With Botox, Dysport, Xeomin, and Jeuveau, gradual return of movement may begin near the end of this period. |
| Months 3–4 | Most Botox, Dysport, Xeomin, and Jeuveau patients notice return of movement and wrinkle recurrence. Re-treatment is typically scheduled. |
| Months 4–6+ | Daxxify patients typically still have meaningful wrinkle reduction at this point. Some Daxxify patients report continued benefit through month 9. |
Clinical Trial Results
In pivotal clinical trials, each product demonstrated statistically significant improvement in glabellar line severity compared to placebo:
| Product | Responder Rate at Day 30 | Median Duration of Effect | Key Trial |
|---|---|---|---|
| Botox | ~80% achieved ≥1 grade improvement | ~3–4 months | Carruthers et al., 2002 |
| Dysport | ~74% achieved ≥2 grade improvement | ~3–4 months | Brandt et al., 2009 |
| Xeomin | ~60% achieved composite endpoint | ~3–4 months | Kane et al., 2015 |
| Jeuveau | ~69% achieved ≥2 grade improvement | ~3–4 months | Solish et al., 2019 |
| Daxxify | ~74% achieved ≥2 grade improvement | ~6 months (median) | Bertucci & Solish, 2022 |
Note: Direct comparison of responder rates between trials is limited because study designs, endpoints, and patient populations were not identical.
Factors Affecting Results
- Etched-in (static) lines: BoNT-A reduces dynamic wrinkles (those that appear with movement). Deep, etched-in lines that are visible at rest may soften with treatment but often do not disappear completely — they may require additional treatments such as dermal fillers, chemical peels, or laser resurfacing.
- Skin quality: Sun-damaged or thinning skin may show less dramatic improvement compared to younger, well-hydrated skin.
- Muscle mass: Patients with stronger or larger muscles (including most male patients) may metabolize the toxin faster and experience shorter duration of effect.
- Metabolism: Highly active individuals and those with fast metabolisms may find that effects wear off sooner (anecdotally reported, though not conclusively proven in studies).
- Treatment history: Patients with a history of regular BoNT-A use often find that results last longer over time, as treated muscles undergo partial disuse atrophy (shrinkage from reduced use).
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Side Effects
Common Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Injection site pain | Common (10–30%) | Brief stinging during injection. Resolves within minutes. |
| Bruising | Common (10–25%) | More likely in patients taking blood thinners, NSAIDs, or certain supplements (fish oil, vitamin E). Typically resolves within 5–10 days. |
| Headache | Common (10–15%) | Mild, transient. Usually resolves within 24–48 hours. More common after forehead treatment. |
| Injection site swelling | Common (5–15%) | Mild edema that resolves within hours to days. |
| Eyelid heaviness | Uncommon (1–5%) | Sensation of heaviness (not true ptosis) when forehead/brow treatment reduces frontalis support. Usually temporary. |
Less Common Side Effects
| Side Effect | Frequency | Notes |
|---|---|---|
| Eyelid ptosis (drooping) | Rare (1–2%) | Occurs when toxin migrates to the levator palpebrae muscle. Resolves as effect wears off (2–6 weeks). Apraclonidine drops may temporarily improve mild ptosis. |
| Brow ptosis | Uncommon (2–5%) | Over-treatment of the frontalis (forehead muscle) without compensating for brow position. More common in patients with low-set brows or excess upper eyelid skin. |
| Asymmetry | Uncommon | Uneven results between sides. Often correctable with a small touch-up injection at follow-up. |
| Flu-like symptoms | Rare | Malaise, mild fatigue, or low-grade fever in the days following treatment. More commonly reported with higher total doses. |
| Difficulty swallowing (dysphagia) | Rare (medical use) | Primarily reported in cervical dystonia treatment where higher doses are used in the neck. Very rare in cosmetic applications. |
Serious Adverse Events
The effects of botulinum toxin may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening, and deaths have been reported. The risk of symptoms is likely greatest in children treated for spasticity, but symptoms can also occur in adults treated for spasticity and other conditions.
In cosmetic applications using standard doses, serious adverse events are extremely rare. The FDA black box warning applies primarily to high-dose medical applications and pediatric spasticity treatment. However, patients should be aware of the theoretical risk and report any unusual symptoms to their provider immediately.
Contraindications
- Known hypersensitivity to botulinum toxin or any formulation component (including human serum albumin for most products)
- Infection at the injection site
- Neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome, ALS) — increased risk of serious complications
- Pregnancy and breastfeeding — not recommended; insufficient safety data
- Aminoglycoside antibiotics or other agents that interfere with neuromuscular transmission — may potentiate effect
Side Effects by Product
Side effect profiles are largely similar across all five products, as they share the same mechanism. Minor differences:
- Dysport: Slightly higher reported rates of headache in some studies, possibly related to broader diffusion (Brandt et al., 2009).
- Xeomin: Lower theoretical risk of immunogenicity (antibody formation) due to absence of complexing proteins.
- Daxxify: In pivotal trials, the most common adverse events were headache (6%), injection site pain, and facial paresis. No unique safety signals compared to other BoNT-A products (Bertucci & Solish, 2022).
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Regulatory Status
FDA Approval Timeline
| Product | First FDA Approval (Medical) | Cosmetic Approval | Regulatory Class |
|---|---|---|---|
| Botox | 1989 (strabismus, blepharospasm) | 2002 (glabellar lines) | Biologic (BLA) |
| Dysport | 2009 (cervical dystonia) | 2009 (glabellar lines) | Biologic (BLA) |
| Xeomin | 2010 (cervical dystonia, blepharospasm) | 2011 (glabellar lines) | Biologic (BLA) |
| Jeuveau | N/A (cosmetic only) | 2019 (glabellar lines) | Biologic (BLA) |
| Daxxify | N/A (cosmetic approval; medical trials ongoing) | 2022 (glabellar lines) | Biologic (BLA) |
Regulatory Classification
All botulinum toxin products are regulated as biologics by the FDA, approved through a Biologics License Application (BLA). This is a higher regulatory standard than a standard drug New Drug Application (NDA). Key implications:
- No generic substitution: Unlike small-molecule drugs, biologic products cannot be automatically substituted with "generic" equivalents. Each botulinum toxin product has a unique manufacturing process and is considered a distinct product.
- cGMP manufacturing: Production facilities are subject to FDA inspection and must comply with current Good Manufacturing Practice (cGMP) standards for biologics.
- Lot-to-lot consistency: Each manufacturing lot undergoes potency testing using standardized bioassays to ensure consistent unit dosing.
- REMS (Risk Evaluation and Mitigation Strategy): All BoNT-A products are subject to a shared REMS program that requires healthcare providers and pharmacies to be enrolled and educated about the risk of toxin spread beyond the injection site.
International Approvals
| Product | EMA (Europe) | Health Canada | TGA (Australia) | MHRA (UK) |
|---|---|---|---|---|
| Botox | Approved | Approved | Approved | Approved |
| Dysport | Approved (as Azzalure for cosmetic) | Approved | Approved | Approved |
| Xeomin | Approved (as Bocouture for cosmetic) | Approved | Approved | Approved |
| Jeuveau | Not approved | Approved (as Nuceiva) | Not approved | Not approved |
| Daxxify | Not yet approved | Not yet approved | Not yet approved | Not yet approved |
Legal Considerations
- Prescription only: All five products require a prescription and must be administered by or under the supervision of a licensed healthcare provider.
- Provider qualifications: Requirements vary by state/jurisdiction. Common qualified providers include dermatologists, plastic surgeons, oculoplastic surgeons, neurologists, nurse practitioners, and physician assistants (scope-of-practice laws vary by state).
- Medical spas: In many jurisdictions, medical spas offering BoNT-A treatments must operate under the supervision of a licensed physician, even if the actual injections are performed by a nurse practitioner or physician assistant.
- Counterfeit products: The FDA has issued warnings about counterfeit botulinum toxin products entering the U.S. market. Patients should verify that their provider sources products directly from authorized distributors.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Cost
Cost Per Unit by Product
| Product | Cost Per Unit | Notes |
|---|---|---|
| Botox | $10–$17 | Premium pricing as the most established brand. Higher-end practices may charge $15–$17/unit. |
| Dysport | $4–$6 | Lower per-unit cost, but more units are required (2.5–3× Botox). Net treatment cost is comparable to Botox. |
| Xeomin | $10–$15 | Often priced slightly below Botox. Some providers offer it as a more affordable alternative with similar efficacy. |
| Jeuveau | $8–$14 | Positioned as a cosmetic-focused, value-priced alternative. Evolus frequently runs promotions and loyalty programs. |
| Daxxify | $12–$20 | Higher per-unit cost, but longer duration (6–9 months) means fewer treatments per year. Annual cost may be comparable to or lower than other products. |
Estimated Cost Per Treatment Area
| Treatment Area | Botox | Dysport | Xeomin | Jeuveau | Daxxify |
|---|---|---|---|---|---|
| Glabellar (women) | $200–$340 | $200–$300 | $200–$300 | $160–$280 | $480–$800 |
| Glabellar (men) | $300–$510 | $300–$480 | $300–$450 | $240–$420 | $720–$1,200 |
| Forehead (women) | $100–$340 | $100–$300 | $100–$300 | $80–$280 | $240–$800 |
| Crow's feet (women, both sides) | $160–$408 | $160–$360 | $160–$360 | $128–$336 | $384–$960 |
| Full upper face (women) | $460–$1,000 | $460–$900 | $460–$900 | $370–$840 | $1,100–$2,400 |
| Full upper face (men) | $690–$1,500 | $690–$1,350 | $690–$1,350 | $555–$1,260 | $1,650–$3,600 |
| Masseter (women, both sides) | $500–$1,700 | $480–$1,440 | $500–$1,500 | $400–$1,400 | $1,200–$4,000 |
Annual Cost Comparison
Because products differ in duration, annual cost is a more meaningful comparison than per-treatment cost:
| Product | Treatments/Year | Estimated Annual Cost (Glabellar, Women) |
|---|---|---|
| Botox | 3–4 | $600–$1,360 |
| Dysport | 3–4 | $600–$1,200 |
| Xeomin | 3–4 | $600–$1,200 |
| Jeuveau | 3–4 | $480–$1,120 |
| Daxxify | 1.5–2 | $720–$1,600 |
Insurance Coverage
- Cosmetic use: Not covered by any insurance plan. All cosmetic BoNT-A treatments are entirely out-of-pocket.
- Medical use (Botox): Insurance may cover Botox for FDA-approved medical indications such as chronic migraine, cervical dystonia, blepharospasm, hyperhidrosis, overactive bladder, and spasticity. Pre-authorization is typically required. Coverage varies by plan.
- HSA/FSA: Botulinum toxin for FDA-approved medical indications may be eligible for Health Savings Account (HSA) or Flexible Spending Account (FSA) reimbursement with proper documentation. Cosmetic use is not eligible.
Loyalty Programs and Discounts
- Allé (Allergan): Points-based rewards program for Botox Cosmetic. Patients earn points on purchases and redeem them for discounts on future treatments.
- Aspire (Galderma): Rewards program for Dysport treatments.
- Xperience+ (Merz): Loyalty program for Xeomin treatments.
- Evolus Rewards: Promotional programs for Jeuveau, often including first-treatment discounts.
- Revance RHA Rewards: Loyalty program that includes Daxxify.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Questions & Answers
Are all botulinum toxin products basically the same?
Answer: All five FDA-approved products share the same core mechanism (blocking acetylcholine release via SNAP-25 cleavage), but they are not interchangeable. They differ in formulation, complexing proteins, diffusion patterns, onset speed, duration, and unit potency. One unit of Botox is not equivalent to one unit of Dysport. Switching between products requires dose conversion and should be managed by an experienced provider (Nestor et al., 2017).
Will I look "frozen" or unnatural?
Answer: The "frozen" look results from over-treatment — using too many units or treating too many areas aggressively. With appropriate dosing by a skilled provider, the goal is to reduce wrinkle-forming movement while preserving natural facial expression. Many providers now favor a "baby Botox" or "micro-dosing" approach that uses slightly lower doses for a more natural, movement-preserving result. Communicating your aesthetic goals clearly with your provider is important.
Does Botox prevent wrinkles from forming?
Answer: There is evidence that regular, long-term BoNT-A use can slow the formation of deep static lines. By reducing repetitive muscle contractions over years, the skin is subjected to less folding stress, which may delay or prevent the etching-in of lines that become visible at rest. This has been observed in clinical practice and supported by long-term follow-up studies, though large randomized prevention trials have not been conducted (Carruthers & Carruthers, 2006).
Is Dysport stronger than Botox?
Answer: Dysport is not "stronger" than Botox — it uses a different unit measurement system. One Dysport unit contains less biological activity than one Botox unit, which is why the conversion ratio is approximately 2.5–3 Dysport units for every 1 Botox unit. When properly converted, the products produce comparable clinical effects at equivalent biological doses (Scaglione, 2016).
Is Daxxify worth the higher cost?
Answer: Daxxify costs more per treatment but lasts approximately 6–9 months compared to 3–4 months for other products. For patients who value fewer office visits, Daxxify may offer a practical advantage. The annual cost can be comparable to other products when the reduced treatment frequency is considered. Whether it is "worth it" depends on individual priorities: convenience, per-visit budget, and how important treatment longevity is to the patient.
Can I develop resistance to Botox?
Answer: True immunoresistance — where the body produces neutralizing antibodies that render BoNT-A ineffective — is possible but rare in cosmetic use, where doses are relatively low. It is more commonly reported in medical applications (e.g., cervical dystonia) where higher doses are used more frequently. Strategies to minimize the risk include using the lowest effective dose, maintaining adequate intervals between treatments (≥12 weeks), and potentially using Xeomin (which lacks immunogenic complexing proteins) (Frevert, 2015).
Why do men need more units?
Answer: Male patients typically have larger, stronger facial muscles — particularly the corrugator, procerus, frontalis, and masseter. Greater muscle mass requires more toxin to achieve adequate relaxation. Men also tend to have thicker skin overlying these muscles. As a result, male dosing is typically 1.5–2× the standard female dose for the same treatment area, which also means higher per-treatment costs.
What age should I start?
Answer: There is no single "right" age to begin BoNT-A treatment. Many providers see patients in their late 20s to early 30s for preventive treatment ("preventive Botox" or "baby Botox"), while others begin when patients first notice bothersome dynamic wrinkles. Starting age depends on individual anatomy, genetics, skin quality, sun exposure history, and personal aesthetic goals. The decision is best made in consultation with a qualified provider.
Is it safe to get Botox during pregnancy?
Answer: Botulinum toxin products are not recommended during pregnancy or breastfeeding. No controlled studies have been conducted in pregnant women. While animal studies have not shown clear teratogenic effects at therapeutic doses, the absence of human safety data means the standard recommendation is to avoid treatment until after pregnancy and breastfeeding are complete.
Further Reading
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.
Key Takeaways
Based on the available evidence:
- Five FDA-approved botulinum toxin type A products are available: Botox, Dysport, Xeomin, Jeuveau, and Daxxify. All share the same core mechanism — blocking acetylcholine release at the neuromuscular junction — but differ in formulation, onset, spread, duration, and cost.
- Units are not interchangeable between brands. Conversion ratios must be used: approximately 1 Botox unit = 2.5–3 Dysport units = 1 Xeomin unit = 1 Jeuveau unit ≈ 2 Daxxify units.
- Most products last 3–4 months. Daxxify is the exception, with a median duration of approximately 6 months and some patients experiencing effects lasting up to 9 months.
- Men typically require 1.5–2× the dose used for women in the same treatment area, due to larger muscle mass and thicker skin.
- Cost ranges from $10–$20 per unit depending on the product and provider. Total treatment costs vary widely based on the areas treated, number of units, gender, and geographic location. Annual costs may be comparable across products when treatment frequency is considered.
- Side effects are generally mild — injection site reactions, bruising, and headache are most common. Serious complications (eyelid ptosis, toxin spread) are rare and typically technique-related.
- All five products are FDA-approved prescription biologics subject to rigorous manufacturing and safety standards. They must be administered by or under the supervision of a licensed healthcare provider.
- Provider skill matters as much as product choice. The experience, anatomical knowledge, and injection technique of the treating provider are often more important determinants of outcome than which specific product is used.
Questions to Ask Your Provider
- Which botulinum toxin product do you recommend for my specific concerns, and why?
- How many units do you anticipate I will need for the areas I want treated?
- What is the total estimated cost, and do you participate in any loyalty or rewards programs?
- What is your experience with this specific product?
- How do you approach dosing to maintain natural expression?
- What should I expect in terms of onset, peak effect, and duration?
- What are the potential risks specific to the areas being treated?
- How frequently will I need retreatment?
This content is for informational and educational purposes only. It is not intended as, and should not be interpreted as, medical advice. The information provided does not cover all possible uses, precautions, interactions, or adverse effects, and may not reflect the most recent medical research or guidelines. It should not be used as a substitute for the advice of a qualified healthcare professional. Never disregard professional medical advice or delay seeking treatment because of something you have read here. Always speak with your doctor or pharmacist before starting, stopping, or changing any prescribed medication or treatment. If you think you may have a medical emergency, call your doctor or emergency services immediately. GLPbase does not recommend or endorse any specific tests, physicians, products, procedures, or opinions. Use of this information is at your own risk.
Sources & Further Reading
Comprehensive Reviews & Comparisons
- Nestor MS, et al. (2017) — "Botulinum Toxin Type A: A Comprehensive Review" — Aesthetic Surgery Journal
- Scaglione F. (2016) — "Conversion Ratio between Botox, Dysport, and Xeomin in Clinical Practice" — Toxins
- Frevert J. (2015) — "Content of Botulinum Neurotoxin in Botox/Vistabel, Dysport/Azzalure, and Xeomin/Bocouture" — Drugs in R&D
Mechanism of Action
- Aoki KR. (2004) — "Botulinum toxin: a successful therapeutic protein" — Current Medicinal Chemistry
- Brunger AT, Bhagat S. (2001) — "Botulinum neurotoxin: structure and mechanism of action" — Annual Review of Biochemistry
Clinical Trials — Pivotal Studies
- Carruthers JA, et al. (2002) — "Botox for glabellar lines: pivotal Phase 3 trial" — Dermatologic Surgery
- Brandt F, et al. (2009) — "Dysport efficacy and safety for glabellar lines" — Clinical Drug Investigation
- Kane MA, et al. (2015) — "Xeomin (incobotulinumtoxinA) efficacy and safety" — Dermatologic Surgery
- Solish N, et al. (2019) — "Jeuveau (prabotulinumtoxinA) Phase 3 results" — Aesthetic Surgery Journal
- Bertucci V, Solish N. (2022) — "DaxibotulinumtoxinA for glabellar lines: duration and efficacy" — Dermatologic Surgery
Dosing & Conversion
- Scaglione F. (2016) — "Conversion ratios between BoNT-A products" — Toxins
- Nestor MS, et al. (2017) — Dosing comparisons across products — Aesthetic Surgery Journal
Immunogenicity
Long-Term Use & Prevention
Medical Applications
- Dodick DW, et al. (2010) — "OnabotulinumtoxinA for chronic migraine — PREEMPT trial" — Headache
- Wollmer MA, et al. (2012) — "Botulinum toxin treatment for depression" — Journal of Psychiatric Research
Regulatory & Safety
- FDA: Botulinum Toxin Products — Safety and Information Page
- FDA: Warnings About Counterfeit Botox Products
This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.